Erminia Massarelli

11.5k total citations · 3 hit papers
140 papers, 4.6k citations indexed

About

Erminia Massarelli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Erminia Massarelli has authored 140 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 83 papers in Pulmonary and Respiratory Medicine and 23 papers in Molecular Biology. Recurrent topics in Erminia Massarelli's work include Lung Cancer Treatments and Mutations (71 papers), Cancer Immunotherapy and Biomarkers (44 papers) and Lung Cancer Research Studies (33 papers). Erminia Massarelli is often cited by papers focused on Lung Cancer Treatments and Mutations (71 papers), Cancer Immunotherapy and Biomarkers (44 papers) and Lung Cancer Research Studies (33 papers). Erminia Massarelli collaborates with scholars based in United States, Australia and Spain. Erminia Massarelli's co-authors include Roy S. Herbst, Ignacio I. Wistuba, Ximing Tang, Diane D. Liu, Marileila Varella‐Garcia, Ana C. Xavier, Natalie Ozburn, Vassiliki A. Papadimitrakopoulou, B. Nebiyou Bekele and Ravi Salgia and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Erminia Massarelli

135 papers receiving 4.5k citations

Hit Papers

KRASMutation Is an Import... 2007 2026 2013 2019 2007 2017 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
    2007 500 citations Erminia Massarelli, Marileila Varella‐Garcia et al. Clinical Cancer Research profile →
  2. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →
  3. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
    2014 255 citations Chad Tang, Erminia Massarelli et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Erminia Massarelli 3.2k 2.1k 1.2k 729 648 140 4.6k
Jean-Pascal Machiels 2.0k 0.6× 2.4k 1.1× 960 0.8× 988 1.4× 848 1.3× 36 4.5k
Neal Ready 4.2k 1.3× 2.8k 1.3× 1.1k 0.9× 741 1.0× 481 0.7× 160 5.7k
Ihor Vynnychenko 4.6k 1.4× 4.3k 2.0× 1.4k 1.1× 456 0.6× 901 1.4× 57 7.0k
Abderrahim Fandi 3.2k 1.0× 3.0k 1.4× 1.1k 0.9× 230 0.3× 552 0.9× 50 4.4k
Matthew G. Fury 2.1k 0.7× 1.3k 0.6× 881 0.7× 338 0.5× 347 0.5× 165 4.4k
Kyuichi Kadota 1.9k 0.6× 3.2k 1.5× 1.1k 0.9× 387 0.5× 571 0.9× 132 5.1k
Rom S. Leidner 2.4k 0.8× 576 0.3× 965 0.8× 1.5k 2.0× 517 0.8× 94 3.7k
Snjezana Doğan 2.0k 0.6× 1.4k 0.7× 1.2k 0.9× 327 0.4× 565 0.9× 89 4.6k
Sanatan Saraf 3.3k 1.0× 1.5k 0.7× 451 0.4× 800 1.1× 447 0.7× 43 4.2k

Countries citing papers authored by Erminia Massarelli

Since Specialization
Citations

This map shows the geographic impact of Erminia Massarelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erminia Massarelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erminia Massarelli more than expected).

Fields of papers citing papers by Erminia Massarelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erminia Massarelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erminia Massarelli. The network helps show where Erminia Massarelli may publish in the future.

Co-authorship network of co-authors of Erminia Massarelli

This figure shows the co-authorship network connecting the top 25 collaborators of Erminia Massarelli. A scholar is included among the top collaborators of Erminia Massarelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erminia Massarelli. Erminia Massarelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sampath, Sagus, Puneeth Iyengar, Song Zhang, et al.. (2025). Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non–small cell lung cancer: a multicentre, single-arm, phase 2 trial. EClinicalMedicine. 87. 103435–103435.
2.
Steuer, Conor, Hidetoshi Hayashi, Wu‐Chou Su, et al.. (2025). Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. Journal of Clinical Oncology. 43(25). 2816–2826. 3 indexed citations
3.
Neal, Joel W., Armando Santoro, María González‐Cao, et al.. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clinical and Research Reports. 5(10). 100666–100666. 2 indexed citations
4.
Ladbury, Colton, Arya Amini, Yi Xiao, et al.. (2024). The impact of pretreatment symptom burden on long‐term quality of life following head and neck radiation: A prospective longitudinal study. Head & Neck. 46(11). 2806–2814. 1 indexed citations
5.
Muddasani, Ramya, Isa Mambetsariev, Erminia Massarelli, et al.. (2024). The clinical utility of a circulating tumor cell based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with metastatic non-small cell lung cancer.. Journal of Clinical Oncology. 42(16_suppl). 8644–8644. 1 indexed citations
6.
Presant, Cary A., Cathee Till, Riha Vaidya, et al.. (2024). Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants. Cancer. 131(1). e35560–e35560. 1 indexed citations
7.
Konda, Bhavana, Eric J. Sherman, Erminia Massarelli, et al.. (2024). Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 110(3). 830–837. 4 indexed citations
8.
9.
Park, Jong Chul, David Berz, Manish Sharma, et al.. (2023). 742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors. SHILAP Revista de lepidopterología. A836–A837. 2 indexed citations
10.
Sanborn, Rachel E., Muhammad Furqan, Manish Sharma, et al.. (2023). 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors. SHILAP Revista de lepidopterología. A844–A844. 1 indexed citations
11.
Pathak, Ranjan, et al.. (2021). Immune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. The Oncologist. 26(12). 1052–1061. 115 indexed citations
12.
Cushman, Taylor R., Bernard L. Jones, David Akhavan, et al.. (2020). The Effects of Time to Treatment Initiation for Patients With Non–small-cell Lung Cancer in the United States. Clinical Lung Cancer. 22(1). e84–e97. 24 indexed citations
13.
14.
Reckamp, Karen L., Jasmine A. McQuerry, Isa Mambetsariev, et al.. (2020). Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With MET Alterations. Future Science OA. 7(2). FSO662–FSO662. 1 indexed citations
15.
Spira, Alexander I., Collin M. Blakely, Kai He, et al.. (2018). Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology. 29. viii400–viii401. 9 indexed citations
16.
Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →
17.
Tang, Chad, James W. Welsh, Patricia M. de Groot, et al.. (2016). Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research. 23(6). 1388–1396. 251 indexed citations
18.
Kies, Merrill S., Floyd Christopher Holsinger, J. Jack Lee, et al.. (2009). Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial. Journal of Clinical Oncology. 28(1). 8–14. 187 indexed citations
19.
Tang, Ximing, Marileila Varella‐Garcia, Ana C. Xavier, et al.. (2008). Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas. Cancer Prevention Research. 1(3). 192–200. 71 indexed citations
20.
Onn, Amir, Arlene M. Correa, Michael Z. Gilcrease, et al.. (2004). Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2- neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer. Clinical Cancer Research. 10(1). 136–143. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean-Pascal Machiels Breakdown of academic impact, for papers by Neal Ready Breakdown of academic impact, for papers by Ihor Vynnychenko Breakdown of academic impact, for papers by Abderrahim Fandi Breakdown of academic impact, for papers by Matthew G. Fury Breakdown of academic impact, for papers by Kyuichi Kadota Breakdown of academic impact, for papers by Rom S. Leidner Breakdown of academic impact, for papers by Snjezana Doğan Breakdown of academic impact, for papers by Sanatan Saraf
Rankless by CCL
2026